Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
CLGN CollPlant Biotechnologies Ltd
- Stocks
- Healthcare
- NASDAQ: CLGN
Price (delayed)
$1.66
Market cap
$19.01M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.22
Enterprise value
$11.12M
collplant is a regenerative medicine company focused on 3d bioprinting of tissues and organs, and on developing and commercializing tissue repair products for orthobiologics, and advanced wound care markets. our
Highlights
The debt has contracted by 8% from the previous quarter and by 6% YoY
The gross margin has soared by 123% from the previous quarter but it has contracted by 39% YoY
The company's net income has shrunk by 85% YoY but it rose by 17% QoQ
CLGN's gross profit has plunged by 86% YoY
The revenue has plunged by 77% YoY
Key stats
What are the main financial stats of CLGN
Market
Valuations
Earnings
Shares outstanding
11.45M
Market cap
$19.01M
Enterprise value
$11.12M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.53
Price to sales (P/S)
7.69
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.5
Revenue
$2.47M
Gross profit
$1.2M
Operating income
-$14.57M
Net income
-$13.87M
EBIT
-$14.37M
EBITDA
-$13.37M
Free cash flow
-$12.42M
Per share
Balance sheet
Liquidity
EPS
-$1.22
EPS diluted
-$1.22
Free cash flow per share
-$1.08
Book value per share
$1.08
Revenue per share
$0.22
TBVPS
$1.49
Total assets
$17.21M
Total liabilities
$4.81M
Debt
$2.84M
Equity
$12.4M
Working capital
$9.39M
Debt to equity
0.23
Current ratio
4.48
Quick ratio
4.14
Net debt/EBITDA
0.59
Margins
Efficiency
Dividend
EBITDA margin
-540.9%
Gross margin
48.7%
Net margin
-560.9%
Operating margin
-589.4%
Return on assets
-65.3%
Return on equity
-87.3%
Return on invested capital
-205.2%
Return on capital employed
-99.1%
Return on sales
-581.5%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CLGN stock price
How has the CollPlant Biotechnologies stock price performed over time
Intraday
15.28%
1 week
22.96%
1 month
16.9%
1 year
-66.8%
YTD
-53.89%
QTD
22.06%
Financial performance
How have CollPlant Biotechnologies's revenue and profit performed over time
Revenue
$2.47M
Gross profit
$1.2M
Operating income
-$14.57M
Net income
-$13.87M
Gross margin
48.7%
Net margin
-560.9%
The gross margin has soared by 123% from the previous quarter but it has contracted by 39% YoY
CLGN's gross profit has plunged by 86% YoY
The company's net income has shrunk by 85% YoY but it rose by 17% QoQ
The net margin has soared by 83% from the previous quarter
Price vs fundamentals
How does CLGN's price correlate with its fundamentals
Growth
What is CollPlant Biotechnologies's growth rate over time
Valuation
What is CollPlant Biotechnologies stock price valuation
P/E
N/A
P/B
1.53
P/S
7.69
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.5
The company's EPS has shrunk by 85% YoY but it rose by 16% QoQ
The P/B is 64% less than the 5-year quarterly average of 3.7 and 54% less than the last 4 quarters average of 2.9
The equity has contracted by 49% YoY and by 8% from the previous quarter
CLGN's price to sales (P/S) is 90% lower than its last 4 quarters average of 65.5 and 89% lower than its 5-year quarterly average of 61.3
The revenue has plunged by 77% YoY
Efficiency
How efficient is CollPlant Biotechnologies business performance
The ROIC has plunged by 162% YoY but it has grown by 17% from the previous quarter
The company's return on sales has surged by 83% QoQ
CLGN's ROA is up by 3.7% since the previous quarter
Dividends
What is CLGN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CLGN.
Financial health
How did CollPlant Biotechnologies financials performed over time
CLGN's total assets is down by 43% year-on-year and by 8% since the previous quarter
The quick ratio has contracted by 40% YoY
The debt is 77% less than the equity
CollPlant Biotechnologies's debt to equity has surged by 92% YoY
The equity has contracted by 49% YoY and by 8% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.